(Q48093756)

8 February 2018

title

Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant (English)

1 reference

8 February 2018

author

Taofeek K. Owonikoko

1

1 reference

8 February 2018

author name string

Mounzer Agha

2

1 reference

8 February 2018

Ronald Balassanian

3

1 reference

8 February 2018

Ryan Smith

4

1 reference

8 February 2018

Anastasios Raptis

5

1 reference

8 February 2018

publication date

1 August 2007

1 reference

8 February 2018

Nature Clinical Practice Oncology

published in

1 reference

8 February 2018

volume

4

1 reference

8 February 2018

issue

8

1 reference

8 February 2018

page(s)

491-495

1 reference

8 February 2018

Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Lymphocyte homing and homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0899

7 January 2021

Identifiers

DOI

10.1038/NCPONC0899

1 reference

8 February 2018

1 reference

8 February 2018